NEOTRIP
Founder
More informations about "NEOTRIP"
Pathologic complete response (pCR) to neoadjuvant …
NeoTRIP is a multicentre open-label study (NCT002620280) in which a total of 280 patients with TNBC were randomized to neoadjuvant carboplatin AUC 2 and nab-paclitaxel 125 mg/m 2 intravenously (i.v.) on days 1 and 8, without (142 …See details»
LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane ...
In NeoTRIP (NCT002620280) addition of atezolizumab to nab-paclitaxel/carboplatin was linked to minor numerical increase of pathologic complete response (pCR) in women with high-risk …See details»
New data from Michelangelo Foundation’s NeoTRIP trial discussed …
Nov 8, 2023 · The NeoTRIP trial promoted by Michelangelo’s Foundation is a phase III clinical trial to evaluate the effects of neoadjuvant therapy with an antibody against PDL-1 in patients with …See details»
Spatial and Compositional Biomarkers in Tumor …
Dec 18, 2023 · The NeoTRIP study randomized patients with TNBC to receive neoadjuvant carboplatin and nab-paclitaxel (chemotherapy) with or without atezolizumab (a PD-L1 …See details»
Triple-negative breast cancer, a ‘special’ imaging to …
Jul 12, 2021 · Designed and conducted by the Michelangelo Foundation, NeoTrip is a phase III clinical trial to evaluate the clinical benefits of adding a neoadjuvant immunotherapy with atezolizumab to chemotherapy with nab-paclitaxel and …See details»
Triple negative breast cancer, new data from …
Feb 28, 2022 · The NeoTRIP trial promoted by Michelangelo’s Foundation is a phase III clinical trial to evaluate the effects of neoadjuvant therapy with an antibody against PDL-1 in patients with locally advanced triple-negative breast …See details»
Highlights on the treatment of High Risk TNBC: The NeoTRIP
Highlights on the treatment of High Risk TNBC: The NeoTRIP Michelangelo study Abstract discussed: LBA19 - Event-free survival (EFS) analysis of the neoadjuvant treatment with or …See details»
In NeoTRIP, Atezolizumab with Neoadjuvant Carboplatin - ESMO
Feb 24, 2022 · Atezolizumab with neoadjuvant carboplatin/nab-paclitaxel was feasible in patients with high-risk early TNBC without limiting immune-related side effects, but it led to modest, …See details»
Pathologic complete response (pCR) to neoadjuvant treatment …
Feb 1, 2022 · NeoTRIP was a trial of early TNBC that compared neoadjuvant chemotherapy (carboplatin and nab-paclitaxel) with chemotherapy plus anti-PD-L1 immunotherapy …See details»
Discontinuation rate and serious adverse events of …
Dec 15, 2023 · Herein, we carried out a comprehensive systematic review and meta-analysis to assess discontinuation rate and serious adverse events of chemoimmunotherapy compared to chemotherapy alone in phase II and III …See details»
Pathologic complete response (pCR) to neoadjuvant treatment …
Feb 17, 2022 · NeoTRIP is a multicentre open-label study (NCT002620280) in which a total of 280 patients with TNBC were randomized to neoadjuvant carboplatin AUC 2 and nab …See details»
Utilizing Neoadjuvant Immunotherapy Combination in Triple …
Apr 8, 2020 · Combination of anti–PD-1 pembrolizumab and anthracycline/taxane-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer (TNBC) results in …See details»
Annals of Oncology abstracts
Background: In NeoTRIP (NCT002620280) addition of atezolizumab to nab-paclitaxel/ carboplatin was linked to minor numerical increase of pathologic complete response (pCR) in women with …See details»
A randomized phase 2 study of neoadjuvant carboplatin and …
Dec 30, 2022 · Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer …See details»
No Improved pCR With Atezolizumab in Early Triple-Negative …
Feb 25, 2020 · NeoTRIP randomly assigned 280 women with early high-risk or locally advanced, unilateral triple-negative breast cancer 1:1 to receive neoadjuvant therapy with either …See details»
Pathologic complete response (pCR) to neoadjuvant treatment …
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo …See details»
(PDF) Spatial predictors of immunotherapy response in triple …
Sep 6, 2023 · Our findings show that multicellular spatial organization is a major determinant of ICB effect and suggest that its systematic enumeration in situ could help realize precision …See details»
Abstract - American Association for Cancer Research
Feb 15, 2020 · Retrospective data showed that a subset of patients have an ongoing immune response within the tumor microenvironment, and that PD-L1 expression is an adaptive …See details»
LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression …
NeoTRIP, randomized 280 pts to 8 cycles of nab-paclitaxel/carbo (CT) or with atezolizumab (CT/A). 260 pts were evaluable for pCR as Per-Protocol Population.See details»